The FDA approved a new blood thinner developed by Merck & Co. (MRK) that is designed to help patients who’ve had a heart attack or suffer from blood clot in the arteries of the legs.
The new drug, called vorapaxar, will be sold under the company’s Zontivity brand.
FDA Director Ellis Unger noted that, “In patients who have had a heart attack or who have peripheral arterial disease, this drug will lower the risk of heart attack, stroke, and cardiovascular death.”
Merck shares were up 1.1% to $55.41 in afternoon trading on Friday. The stock is near the top-end of the 52-week range set between $44.62 and $59.84.
Latest posts by David Warren (see all)
- New World War 2 Inspired Call of Duty in the Making - Mar 26, 2017
- Arctic Sea Ice Loss Contributed to Chinese Smog - Mar 17, 2017
- STD-Infected Moms Twice More Likely to Conceive a Baby with Autism Spectrum Disorder - Feb 27, 2017